Efficacy and safety of evolocumab in reducing lipids and cardiovascular events
10.1056/nejmoa1500858 · 2015
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events
10.1056/nejmoa1501031 · 2015
Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia
10.1016/j.amjcard.2015.02.006 · 2015
PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels
10.1016/j.pharmthera.2014.07.004 · 2015
Normalization of low-density lipoprotein receptor expression in receptor defective homozygous familial hypercholesterolemia by inhibition of PCSK9 with alirocumab
10.1016/j.jacc.2014.07.995 · 2014
Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)
10.1161/circulationaha.113.004406 · 2014
Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials
2014
Lipoprotein(a) metabolism
10.1097/mol.0000000000000070 · 2014
Lipoprotein(a) levels in hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation
10.1016/j.jacc.2014.01.063 · 2014
Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality
10.1001/jama.2009.1063 · 2009
Lipoprotein(a): resurrected by genetics
10.1111/j.1365-2796.2012.02592.x · 2013
The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate
10.1172/jci117292 · 1994
Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies
10.1016/j.jacc.2012.04.038 · 2012
Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor
10.1074/jbc.m114.611988 · 2015
Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects
10.1016/j.jacc.2014.02.538 · 2014
Effects of extended-release nicotinic acid on apolipoprotein (a) kinetics in hypertriglyceridemic patients
10.1161/atvbaha.115.305835 · 2015
Functional characterization and classification of frequent low-density lipoprotein receptor variants
10.1002/humu.22721 · 2015
Cellular uptake of lipoprotein[a] by mouse embryonic fibroblasts via the LDL receptor and the LDL receptor-related protein
10.1016/s0022-2275(20)37140-6 · 1997
Identification of megalin/gp330 as a receptor for lipoprotein(a) in vitro
10.1161/01.atv.19.3.552 · 1999
Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia
10.1161/circulationaha.113.004678 · 2013
The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans
10.1172/jci117794 · 1995
On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects
10.1016/j.atherosclerosis.2014.12.017 · 2015
Loss of plasma proprotein convertase subtilisin/kexin 9 (PCSK9) after lipoprotein apheresis
10.1161/circresaha.113.302655 · 2013
